High growth at low margins is better than the reverse, says Novo Nordisk CEO Novo Nordisk's growth is a sign of its products' well-being on the market, says CEO Lars Fruergaard Jørgensen. "Growth is the best indicator for future success," he tells Danish media Børsen. Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup/ERH by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen Published: 28.12.21 at 09:34 The strongest growth in many years, perhaps ever. This is how CEO at Novo Nordisk Lars Fruergaard Jørgensen describes his firm's current advancements in an interview with Danish business daily Børsen. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch Extra data boosts Lundbeck's agitation case Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients. FDA confirms rejection of Y-mabs' cancer drug The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October. Top news from MedWatch this week Miss anything? Acquisitions to help Coloplast attain growth goal Coloplast aims to grow by 10%, and chairman of the board Lars Rasmussen thinks this will be realized through multiple acquisitions. FDA approves Ferring microbiotica-based treatment Ferring Pharmaceuticals has received US approval for its stomach infection treatment. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading Novo reaches share milestone, analyst credits Wegovy Novo Nordisk stresses importance of keeping production going during an energy crisis Denmark recommends Lundbeck migraine treatment Top news from MedWatch this week FDA approves Ferring microbiotica-based treatment Related articles Novo CEO is on the hunt for future growth: "The pressure is bigger than ever" Novo Nordisk must stay ready to increase Wegovy sales, says CFO Novo CEO on US obesity drug demand: "It was the perfect storm"